|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2002-5-2
|
|
pubmed:abstractText |
HER-2/neu gene amplification and cell surface overexpression are important factors in breast cancer for prognosis and prediction of sensitivity to anti-HER-2/neu monoclonal antibody therapy. In lung cancer, the clinical significance of HER-2/neu expression is currently under evaluation. We investigated 238 non-small lung carcinomas for HER-2/neu protein overexpression by immunohistochemistry using the HercepTest. We found 2+ or 3+ overexpression in 39 patients (16%), including 35% in adenocarcinomas and 20% in large cell carcinomas, but only 1% of squamous cell carcinomas. Marked (3+) overexpression was uncommon (4%). The association between protein expression and gene copy number per cell, as determined by fluorescence in situ hybridisation assay, was investigated in 51 of these NSCLC tumours. Twenty-seven tumours (53%) were negative by both tests. Marked (3+) protein expression and gene amplification were present in only 4% of samples. In 11 tumours (21%), gene gain was accompanied by chromosomal aneusomy and did not result in high protein levels while in 7 (14%) the score 2+ was associated with maximum number of signals per cell <9. The prognostic implication of HER-2/neu protein expression was studied in 187 surgically resected tumours. No statistical difference in survival was observed comparing patients with positive (2+/3+) and negative tumours (0/1+), although 3+ patients showed a tendency to shorter survival. The therapeutic implications of protein expression and gene amplification in lung cancer need to be examined in prospective clinical trials.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-10561247,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-10561337,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-10664619,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-10664627,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-10821485,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-11054438,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-11248153,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-11304680,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-11406656,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-11448895,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-11694786,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-1349163,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-14700481,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-1683776,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-17842433,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-1972347,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-1974168,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-2470152,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-2569928,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-2878363,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-2999974,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-3798106,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-7909495,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-8098377,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-8700555,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11986780-9800799
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2002 Cancer Research UK
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
6
|
|
pubmed:volume |
86
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1449-56
|
|
pubmed:dateRevised |
2010-9-14
|
|
pubmed:meshHeading |
pubmed-meshheading:11986780-Aged,
pubmed-meshheading:11986780-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:11986780-Female,
pubmed-meshheading:11986780-Gene Amplification,
pubmed-meshheading:11986780-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:11986780-Humans,
pubmed-meshheading:11986780-Immunohistochemistry,
pubmed-meshheading:11986780-In Situ Hybridization, Fluorescence,
pubmed-meshheading:11986780-Lung Neoplasms,
pubmed-meshheading:11986780-Male,
pubmed-meshheading:11986780-Microscopy, Fluorescence,
pubmed-meshheading:11986780-Middle Aged,
pubmed-meshheading:11986780-Prognosis,
pubmed-meshheading:11986780-Receptor, erbB-2,
pubmed-meshheading:11986780-Survival Analysis
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas.
|
|
pubmed:affiliation |
Department of Pathology, Campus Box B216, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Denver, Colorado, CO 80262, USA. Fred.Hirsch@uchsc.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
